Clinical Trials Logo

Clinical Trial Summary

This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock.

Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) has been found to be an effective resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An increase in cardiac output during resuscitation is mainly attributed to an increase in stroke volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic receptors to reduce sympathetic activity and systemic vascular resistance.


Clinical Trial Description

Approximately 105 patients will be randomized 2:1 into 2 treatment groups after meeting the eligibility criteria. Total 70 patients will be enrolled in PMZ-2010 group (Group 1) and in Normal Saline group (Group 2) total 35 patients will be enrolled.

- Group 1: PMZ-2010 (Dose: 0.01 mg/kg) + Standard of care

- Group 2: Normal Saline (Dose: Equal volume) + Standard of care In both treatment groups, patients will be provided the standard of care. PMZ-2010 or Normal Saline will be administered intravenously after randomization to hypovolemic shock patients with systolic arterial blood pressure ≤ 90 mmHg at presentation and continue to receive standard Shock Treatment. In PMZ-2010 group, dose of PMZ-2010 (0.01 mg/kg) will be administered as an intravenous (IV) infusion over 1 hour in 100 mL of normal saline. Second dose of PMZ-2010 will be administered if SBP falls below or remains below or equal to 90 mmHg but not before 4 hours of previous dose and total doses per day (in 24 hours) will not exceed 3 doses. PMZ-2010 administration if needed will continue for two days post randomization. Minimum 1 dose or maximum 6 doses of PMZ-2010 will be administered within first 48 hours. post randomization. In Control group, single dose of equal volume of Normal Saline will be administered as intravenous (IV) infusion over 1 hour in 100 mL of normal saline post randomization. Condition of administration will remain same as for PMZ-2010 group. Each patient will be monitored closely throughout his/her hospitalization and will be followed until discharge from randomization. Each patient will be assessed for efficacy parameters over 28 days from randomization to a clinic visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04045327
Study type Interventional
Source Pharmazz, Inc.
Contact
Status Completed
Phase Phase 3
Start date January 31, 2019
Completion date September 27, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05251181 - A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent Phase 3
Completed NCT00488462 - Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe N/A
Withdrawn NCT05661773 - Digital Ischemia Reduction in Critically Ill Patients N/A
Completed NCT02924792 - Sternal Intraosseous Transfusion of Autologous Whole Blood: A Comparison of Flow Rates and Degree of Hemolysis N/A
Completed NCT02675725 - Kinetics of the Sublingual Microcirculation During Fluid Bolus
Completed NCT04056065 - PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock Phase 2
Completed NCT02772653 - Evaluation of Resuscitation Markers in Trauma Patients
Completed NCT02584803 - Inferior Vena Cava Assessment in Term Pregnancy Using Ultrasound: a Feasibility Study of Subxiphoid and RUQ Views
Terminated NCT01653977 - Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery N/A
Recruiting NCT05931601 - Early Initiated Vasopressor Therapy in the Emergency Department Phase 3
Completed NCT02558166 - Renal Resistive Index in Patients With Shock N/A
Recruiting NCT05956418 - A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients Phase 4
Recruiting NCT02046785 - Hemodynamic Measurements at Different Inclinations of the Head N/A
Completed NCT00305253 - Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt Phase 1/Phase 2